19 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2039. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2039
Next term end
10
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2040 · Medium confidence
Also notable
Ends Feb 2041 · High confidence
Also notable
Ends Aug 2039 · High confidence
Also notable
Ends Jul 2041 · High confidence
Also notable
Ends Jun 2043 · High confidence
Fluoroalkyl-Oxadiazoles and Uses Thereof
US 11,578,066
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2040.
Gene Therapy Vectors for Treating Heart Disease
US 11,446,397
A family of 6 related applications built on the 2022 grant. Protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
Cardiac Cell Reprogramming with Myocardin and ASCL1
US 11,015,211
A family of 5 related applications built on the 2021 grant. Protection runs to 2039.
PLAKOPHILLIN-2 Gene Therapy Methods and Compositions
US 11,781,156
Granted 2023. Computed term ends 2041.
Adeno-Associated Virus with Engineered Capsid
US 12,630,841
Granted 2026. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 19, 2027The maintenance fee for Gene Therapy Vectors for Treating Heart Disease (US 11,759,531) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Apr 10, 2027The maintenance fee for PLAKOPHILLIN-2 Gene Therapy Methods and Compositions (US 11,781,156) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Cardiac Cell Reprogramming with Myocardin and ASCL1 (US 11,913,012) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Fluoroalkyl-Oxadiazoles and Uses Thereof (US 11,926,622) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
The largest of its 10 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Gene Therapy Vectors for Treating Heart Disease | 5 in force | to Feb 2041 |
| Fluoroalkyl-Oxadiazoles and Uses Thereof | 3 in force | to Dec 2040 |
| Cardiac Cell Reprogramming with Myocardin and ASCL1 | 3 in force | to Aug 2039 |
| Adeno-Associated Virus with Engineered Capsid (2021) | 2 in force | to Jun 2043 |
| Adeno-Associated Virus with Engineered Capsid (2022) | 1 in force | to Aug 2042 |
| Optimized Expression Cassettes for Gene Therapy (2022) | 1 in force | to Jul 2042 |
| Optimized Expression Cassettes for Gene Therapy (2023) | 1 in force | to Jul 2042 |
| PLAKOPHILLIN-2 Gene Therapy Methods and Compositions (2021) | 1 in force | to Jul 2041 |
| PLAKOPHILLIN-2 Gene Therapy Methods and Compositions (2023) | 1 in force | to Jul 2041 |
| HDAC6 Inhibitors for Treatment of Metabolic Disease and Hfpef | 1 in force | to Dec 2040 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,015,211 | Cardiac Cell Reprogramming with Myocardin and ASCL1 In force · High confidence | In force | High confidence | |
| US 11,913,012 | Cardiac Cell Reprogramming with Myocardin and ASCL1 In force · High confidence | In force | High confidence | |
| US 12,168,778 | Cardiac Cell Reprogramming with Myocardin and ASCL1 In force · High confidence | In force | High confidence | |
| US 12,104,165 | Adeno-Associated Virus with Engineered Capsid In force · Medium confidence | In force | Medium confidence | |
| US 11,578,066 | Fluoroalkyl-Oxadiazoles and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,926,622 | Fluoroalkyl-Oxadiazoles and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,201,617 | HDAC6 Inhibitors for Treatment of Metabolic Disease and Hfpef In force · High confidence | In force | High confidence | |
| US 12,312,345 | Fluoroalkyl-Oxadiazoles and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 11,129,908 | Gene Therapy Vectors for Treating Heart Disease In force · High confidence | In force | High confidence | |
| US 11,446,397 | Gene Therapy Vectors for Treating Heart Disease In force · High confidence | In force | High confidence |
Also on record, not counted in the 19: 19 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.